Mounjaro (Tirzepatide) Injection 2.5

Eli Lilly and Company is proud to announce that the U.S. Food and Drug Administration (FDA) approved Mounjaro (tirzepatide) injection for the treatment of adults with type 2 diabetes as an adjunct to diet and exercise. The approval of Mounjaro represents the first new class of diabetes medication introduced in nearly a decade.

Mounjaro is the first and only approved once-weekly GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. It is a single molecule that targets the body’s receptors for GIP and GLP-1, which are natural incretin hormones. Results from the global phase 3 SURPASS program supported this approval.